Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bausch + Lomb Corporation Common Shares (NY:BLCO)

11.51 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jun 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch + Lomb Corporation Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall
From Bausch + Lomb Corporation
Via Business Wire
3 Reasons to Sell BLCO and 1 Stock to Buy Instead
Bausch + Lomb has gotten torched over the last six months - since October 2024, its stock price has dropped 41.5% to $12.06 per share. This might have investors contemplating their next move. 
Via StockStory
Topics Bankruptcy
Exposures Financial Legal
Earnings Scheduled For February 19, 2025
Via Benzinga
3 of Wall Street’s Favorite Stocks in the Doghouse
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Topics Firearms
Exposures Firearms
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & Supplies - Specialty Segment
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Bausch + Lomb (NYSE:BLCO) and its peers. 
Via StockStory
Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and... 
Via StockStory
Why Bausch + Lomb (BLCO) Shares Are Plunging Today
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 6.7% in the morning session after Wells Fargo downgraded the stock's rating from Buy to Hold. The firm cited concerns related to the "voluntary... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday
Via Benzinga
Why Bausch + Lomb (BLCO) Stock Is Nosediving
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall was... 
Via StockStory
Topics Artificial Intelligence Initial Public Offering
Exposures Artificial Intelligence Securities Market
Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30
From Bausch + Lomb Corporation
Via Business Wire
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
From Bausch + Lomb Corporation
Via Business Wire
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
3 Stocks Under $50 Walking a Fine Line
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises
The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China. 
Via Stocktwits
Topics Earnings
Exposures Financial
Globus Medical (GMED) Q4 Earnings: What To Expect
Medical device company Globus Medical (NYSE:GMED) will be announcing earnings results tomorrow after the bell. Here’s what to expect. 
Via StockStory
Earnings To Watch: Integer Holdings (ITGR) Reports Q4 Results Tomorrow
Medical technology company Integer Holdings (NYSE:ITGR) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Bausch + Lomb’s (NYSE:BLCO) Q4: Beats On Revenue
Eyecare company Bausch + Lomb (NYSE:BLCO) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 9.1% year on year to $1.28 billion. On the other hand, the company’s full-year... 
Via StockStory
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect
Eyecare company Bausch + Lomb (NYSE:BLCO) will be announcing earnings results tomorrow morning. Here’s what to expect. 
Via StockStory
Deal Dispatch: PharmChem Forgoes Banker To Run Sale, TGI Fridays Sells 19 Restaurants For $3.1 Million
Bausch + Lomb's efforts to sell have so far been unsuccessful. Meanwhile, KKR is aggressively pursuing a deal for Fuji Soft. 
Via Benzinga
Bausch + Lomb Provides Update on Potential Sale
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19
From Bausch + Lomb Corporation
Via Business Wire
Aehr Test Systems Posts Weak Results, Joins Trump Media & Technology Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Government
Exposures Political
Bausch + Lomb Bolsters Pipeline with Acquisition of Whitecap Biosciences
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb Launches enVista Aspire™ Intermediate Optimized Monofocal and Toric Intraocular Lenses in the European Union
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb and Glaucoma Research Foundation Launch Second Annual “Faces of Glaucoma” Campaign and Fundraising Challenge
From Bausch + Lomb Corporation
Via Business Wire
Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.